Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

Abstract: Reconfigurable arrays enable flexible utilization of system resources, and thus become a key technology in modern radar and communication systems. Once the array is reconfigured, its ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Birgitta Böckeler, Distinguished Engineer at ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Abstract: The forgetting factor is the main control parameter of the recursive least-squares (RLS) algorithm, which is set to balance between the estimate accuracy and the tracking capability.

You’re at the checkout screen after an online shopping spree, ready to enter your credit card number. You type it in and instantly see a red error message ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...

AI drug discovery specialist Recursion Pharmaceuticals is shelving three of its most advanced drug prospects in an effort to cut costs following a merger last year. Alongside its latest quarterly ...